1. Introduction {#sec1-medicina-55-00138}
===============

The prevalence of Type 2 Diabetes Mellitus (T2DM) and the corresponding demand for its management is proving to be a global economic burden \[[@B1-medicina-55-00138]\]. Various strategies, including dietary management, exercise-based therapies, novel drug development, personalized medicine, pharmacotherapy, pathogenesis, traditional medicines, and combined anti-diabetic or 'anti-hyperglycemic' therapies are prioritized as various methods for treatment and prevention of T2DM globally \[[@B1-medicina-55-00138]\].

Herbal treatments and traditional plant-based medicines have become increasingly popular, as convenient and low-cost options with potentially fewer side effects \[[@B1-medicina-55-00138]\]. Herbal or plant-based anti-hyperglycemic treatments are reportedly targeted to biochemical pathways, including antioxidant/free radical pathways based on hyperglycemia being associated with mitochondria overproduction of free radicals \[[@B1-medicina-55-00138],[@B2-medicina-55-00138]\]. Additionally, there is increasing interest in management strategies for T2DM and its prevention based on alternative low-cost nutrition strategies, including plant-based functional-foods \[[@B2-medicina-55-00138]\]. However, currently, consensus has only been reached regarding the anti-hyperglycemic effect relating to the high-fiber content of many of the proposed anti-hyperglycemic functional foods. This is primarily based on the fiber content slowing the rate of digestion and the resultant altered rate of glucose absorption \[[@B2-medicina-55-00138]\].

Worldwide, there is a focus on sustainable and responsible preventative health interventions, with the emphasis on socio-political, economic and environmental factors \[[@B3-medicina-55-00138]\]. The social push to include environmental factors has led to the consideration of the effectiveness of low-resource intensive plant-based treatments for the maintenance and prevention of T2DM. This includes the potential therapeutics derived from cacti \[[@B3-medicina-55-00138],[@B4-medicina-55-00138]\]. Specifically, *Opuntia spp.* cacti, with a strong history of use as a treatment of hyperglycemia in traditional medicine \[[@B4-medicina-55-00138]\], will be the focus of this systematic review. The *Opuntia spp.* cacti is utilized as a source of food, hedge plant, or as an ornamental plant, particularly in arid and drought-affected regions, becoming more relevant with environmental cases of desertification \[[@B5-medicina-55-00138],[@B6-medicina-55-00138],[@B7-medicina-55-00138],[@B8-medicina-55-00138]\]. The cacti as a crop is utilized, particularly on non-productive agricultural lands, for its resources, that include the fruit, the Prickly Pear (PP) and leaf, the cladode \[[@B5-medicina-55-00138],[@B6-medicina-55-00138],[@B7-medicina-55-00138],[@B8-medicina-55-00138]\]. The *Opuntia spp.* cacti is reported to have 'anti-hyperglycemic' and 'anti-diabetic' properties in humans and it is prescribed in many traditional and complementary therapies around the world \[[@B9-medicina-55-00138],[@B10-medicina-55-00138],[@B11-medicina-55-00138],[@B12-medicina-55-00138]\]. However, confusion exists within the literature as to which principal cacti component is potentially responsible for such effects. Clarification of this issue could enhance the use of PP for treatment, maintenance, and prevention of chronic diseases and affect progress in the development of new potential anti-hyperglycemic agents.

To be able to further consider *Opuntia spp.* components for new anti-hyperglycemic agents, there is a need to identify which component(s), if any, are the true source of any potential anti-hyperglycemic effects of *Opuntia spp*. There are obvious compositional variations between the leaf and fruit which require investigation to define any possible resultant health associations \[[@B4-medicina-55-00138]\]. The fruit of the cacti is also referred to as the 'cactus fruit' or 'Indian fig' and also as the PP \[[@B6-medicina-55-00138],[@B7-medicina-55-00138]\] is predominantly known for relatively high levels of macro- and micronutrients including fiber, mineral composition, numerous amino acids; and significant lipid and phytosterol content \[[@B13-medicina-55-00138],[@B14-medicina-55-00138],[@B15-medicina-55-00138],[@B16-medicina-55-00138],[@B17-medicina-55-00138]\]. In addition, there are a number of different bioactive compounds found in PP such as polyphenols \[[@B18-medicina-55-00138],[@B19-medicina-55-00138]\], flavonols \[[@B19-medicina-55-00138],[@B20-medicina-55-00138],[@B21-medicina-55-00138]\] and betalains \[[@B18-medicina-55-00138],[@B22-medicina-55-00138],[@B23-medicina-55-00138]\], as well as considerably strong antioxidant characteristics \[[@B17-medicina-55-00138],[@B18-medicina-55-00138],[@B20-medicina-55-00138],[@B21-medicina-55-00138],[@B24-medicina-55-00138],[@B25-medicina-55-00138],[@B26-medicina-55-00138],[@B27-medicina-55-00138],[@B28-medicina-55-00138],[@B29-medicina-55-00138],[@B30-medicina-55-00138],[@B31-medicina-55-00138]\]. The PP fruit is commonly consumed fresh, although it can be formulated into several different including dried fruits, tea's, jams, drinks, tinctures and dietary supplements \[[@B6-medicina-55-00138],[@B32-medicina-55-00138],[@B33-medicina-55-00138]\].

The *Opuntia spp.* cacti leaves, often termed the 'cladode' are commonly eaten as a broiled or grilled food product. The cladodes' compositional content varies substantially from the fruit, although it does share common features to include high fiber, mineral, and selection of different bioactives \[[@B34-medicina-55-00138]\]. Similar to PP, the cladode has been extensively investigated for bioactive compounds to include extensive phenolic analysis and antioxidant characterization of various extracts \[[@B34-medicina-55-00138]\]. More recently, the cladode was used in various forms in the food and supplements market such as various pickled products, fiber powders, or capsule-based supplements \[[@B35-medicina-55-00138],[@B36-medicina-55-00138]\].

Therefore, based on the current findings, the primary aim of this systematic literature review is to examine the evidence drawn from well-controlled human clinical trials on the effect of consumption on *Opuntia spp.* cacti on blood glucose (GLU) and insulin levels (INS) in humans. The outcomes of this systematic review will potentially assist clinicians with decisions regarding the use of *Opuntia spp*. product (fruit, leaf or combined) consumption, for improvement of T2DM associated clinical measures such as hyperglycemia or insulin regulation.

2. Materials and Methods {#sec2-medicina-55-00138}
========================

This systematic literature review was conducted following the PRISMA 2009 guidelines \[[@B37-medicina-55-00138]\], and searches were performed in six electronic databases: Food Science and Technology Abstracts (EBSCO), Medline, Scopus, CINAHL, Web of Science and Cochrane databases. The generated results were screened for relevance by title, abstracts and full text ([Figure 1](#medicina-55-00138-f001){ref-type="fig"}), with additional hand searches of included articles reference lists. Results were limited to human quantitative intervention trials based on the consumption of *Opuntia spp.*, investigating the effects on blood GLU or INS resistance parameters, published in English, in peer-reviewed journals since the journal inception. No limitations were made regarding age, gender, race or ethnicity. This systematic literature review is also registered with the PROSPERO registry of the systematic literature reviews held at the University of York (CRD42018108765).

2.1. Search Terminology and Selection Criteria {#sec2dot1-medicina-55-00138}
----------------------------------------------

The following search terms were used, to produce the database outputs: "('Opuntia' OR "Prickly Pear" OR "Cactus fruit" OR "Tuna fruit" OR "Indian fig" OR 'Nopal' OR 'Cladode' OR "Cactus Leaf" OR 'Stems') AND ('Glucose' OR 'Blood glucose' OR 'Glucose tolerance' OR 'Impaired glucose' OR 'Oral glucose' OR 'Glucose metabolism' OR 'glycemia' OR 'Glycaemia' OR 'Hyperglycemia' OR 'Fasting blood glucose' OR 'Glycemic Index' OR 'HOMA' OR 'QUICKI' OR 'GI' OR 'Insulin' OR 'Insulin resistance' OR 'Plasma insulin' OR 'Insulin secretion'). Eligibility for inclusion was determined via satisfaction of criteria; human, in vivo, quantitative intervention trials with control groups or placebo, consumption of *Opuntia spp.* and published since journal inception until September 2018 (5th). The reference lists of included articles were searched for similar phrases and screened for relevance.

2.2. Data Extraction and Outcomes of Interest {#sec2dot2-medicina-55-00138}
---------------------------------------------

Data extraction was conducted independently by two reviewers (C.G., and N.N.) who assessed the eligibility of imported EndNote (v8, Thomas Reuters, Eagan, MN, USA) citations from the database outputs, after removing duplicates. Excluded articles within the screening of titles, abstracts, and full-text articles were excluded on consensus, where disagreement was resolved via discussion. In total, 37 full-text articles were selected for review; and only 20 were included in this systematic review. Prompting reference list searches of included articles, no further articles were identified as suitable for inclusion in this review. Primary outcomes of interest for this systematic review included measures of blood or serum GLU and INS, including biochemical assays, or well-known tools, Homeostatic Model Assessment (HOMA) and 'Quantitative Insulin Sensitivity Check Index' (QUICKI).

2.3. Data Analysis {#sec2dot3-medicina-55-00138}
------------------

Overall studies were evaluated on; risk of bias; study characteristics to include sample size; and participant characteristics including age and gender, study design and intervention. More specifically tools of analysis and reported outcomes were also analyzed to make meaningful conclusions. Due to the heterogenicity of different food products and non-quantifiable composition of some macro- and micronutrients in the provided treatments (food and/or supplement) a meta-analysis was not deemed suitable.

2.4. Risk of Bias {#sec2dot4-medicina-55-00138}
-----------------

The risk of bias for each included study was evaluated using the 'Cochrane Risk of Bias Tool' \[[@B38-medicina-55-00138]\]. The forms of bias considered included; selection, performance, detection, attribution, reporting and 'other' biases, which were scored either 'low', 'high' or 'unclear'.

3. Results {#sec3-medicina-55-00138}
==========

3.1. Search in Literature {#sec3dot1-medicina-55-00138}
-------------------------

Of the 335 results, 20 articles met the inclusion criteria ([Figure 1](#medicina-55-00138-f001){ref-type="fig"}). After removal of duplicates, the included articles were substantially reduced by title and abstract relevance screening (258 removed). Searches of the included article reference lists which did not yield any additional studies were unsuccessful in recruiting additional literature for inclusion. Remaining articles were progressed to full-text screening, where results were filtered to include 20 manuscripts investigating consumption associated effects of various components of the *Opuntia spp*. on blood GLU and INS resistance measures. Of the included studies; four studies \[[@B39-medicina-55-00138],[@B40-medicina-55-00138],[@B41-medicina-55-00138],[@B42-medicina-55-00138]\] investigated the *Opuntia spp*. fruit ([Table 1](#medicina-55-00138-t001){ref-type="table"}), twelve studies \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B45-medicina-55-00138],[@B46-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138],[@B51-medicina-55-00138],[@B52-medicina-55-00138],[@B53-medicina-55-00138],[@B54-medicina-55-00138],[@B55-medicina-55-00138]\] investigated the *Opuntia spp*. cladode ([Table 2](#medicina-55-00138-t002){ref-type="table"}), and four studies \[[@B36-medicina-55-00138],[@B51-medicina-55-00138],[@B56-medicina-55-00138],[@B57-medicina-55-00138]\] investigated unspecified or combinations of both the *Opuntia spp*. fruit and cladode ([Table 3](#medicina-55-00138-t003){ref-type="table"}).

The included studies were scored for risk of bias ([Table 4](#medicina-55-00138-t004){ref-type="table"}) by two researchers (C.G. and N.N.) following the Cochrane Risk of Bias Tool \[[@B38-medicina-55-00138]\]. Investigations into single plant products (fruit; cladode) tended to have a high selection (3; 3) and performance bias (3; 9), with the exception of Wiese et al. (2004) \[[@B41-medicina-55-00138]\] and Bacardi-Gascon et al. (2007) \[[@B55-medicina-55-00138]\]. Across all included studies, detection bias was rated as high, or unclear, if not detailed within the methodology of the article. Reporting bias was consistently low for all included studies.

3.2. Results of Included Studies {#sec3dot2-medicina-55-00138}
--------------------------------

### 3.2.1. Results of *Opuntia spp*. Fruit Included Studies {#sec3dot2dot1-medicina-55-00138}

The studies included in the category of the PP fruit ([Table 1](#medicina-55-00138-t001){ref-type="table"}), utilized various forms such fruit pulp \[[@B40-medicina-55-00138]\], the juice from the fruit pulp \[[@B39-medicina-55-00138]\], fruit peel \[[@B42-medicina-55-00138]\] and fruit extracts \[[@B41-medicina-55-00138]\]. Nearly all of these studies were conducted in males, except for one study conducted in females *(n* = 10 female; T2DM) \[[@B42-medicina-55-00138]\] and one in males and females (*n* = 55; 18 female; 37 male) \[[@B41-medicina-55-00138]\]. Typically, studies in this category were matched with placebo treatments (capsule) \[[@B41-medicina-55-00138]\] or control treatments (GLU control solution, dietary patterns) \[[@B39-medicina-55-00138],[@B40-medicina-55-00138],[@B42-medicina-55-00138]\] and duration of treatment ranged from single consumption \[[@B41-medicina-55-00138],[@B42-medicina-55-00138]\], short term (2--5 weeks) \[[@B39-medicina-55-00138],[@B42-medicina-55-00138]\] and long term (16 weeks) \[[@B40-medicina-55-00138]\].

Supplementation with the purple PP fruit pulp juice over the period of two weeks \[[@B39-medicina-55-00138]\] resulted in significant differences in fasting GLU levels in 'healthy' males undergoing an exercise intervention (*p* = 0.01). Wolfram et al. (2002) \[[@B40-medicina-55-00138]\] using a PP fruit pulp (250 g/day; 8 weeks) also reported significant decreases in fasting GLU (*p* \< 0.005) of participants with hypercholesterolemia and hyperlipidemia; and INS (*p* \< 0.005) in participants with hypercholesterolemia but not hyperlipidemia (*p* \> 0.05). Pimienta et al. (2008) \[[@B42-medicina-55-00138]\] reported no significant effects of PP fruit after a single consumption of PP fruit peel, in 'healthy' subjects (*n* = 14; *p* \> 0.05). Similarly, there were no significant lowering effects inT2DM participants (*n* = 10) after 5 weeks of treatment for both blood GLU and INS (Both *p* \> 0.05), using Oral GLU Tolerance Tests (OGTT) and 'pre-' and 'post-' intervention serum samples. In addition, Wiese et al. \[[@B41-medicina-55-00138]\] examined the effect of commercially available PP fruit extract capsules on reducing symptom severity in 'healthy' participants with induced alcohol toxicity and reported no significant differences between treatment and placebo on serum GLU (*p* \> 0.05).

### 3.2.2. Results of *Opuntia spp*. Cladode Included Studies {#sec3dot2dot2-medicina-55-00138}

Studies on the cladode of *Opuntia spp.* included numerous preparations of these products as a food delivery method such as; cooked (broiled, grilled) \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B47-medicina-55-00138],[@B54-medicina-55-00138]\], powders \[[@B45-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138]\], capsules \[[@B52-medicina-55-00138],[@B53-medicina-55-00138]\] and new products such as tortillas including the cladode \[[@B55-medicina-55-00138]\]. The cladode was studied in; 'healthy' \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B45-medicina-55-00138],[@B46-medicina-55-00138],[@B48-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138],[@B51-medicina-55-00138],[@B52-medicina-55-00138]\], obese \[[@B46-medicina-55-00138],[@B52-medicina-55-00138]\], T2DM \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B45-medicina-55-00138],[@B46-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B50-medicina-55-00138],[@B54-medicina-55-00138],[@B55-medicina-55-00138]\] participants as control \[[@B45-medicina-55-00138],[@B46-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138],[@B51-medicina-55-00138],[@B52-medicina-55-00138]\] and cross-over trials \[[@B50-medicina-55-00138],[@B53-medicina-55-00138],[@B54-medicina-55-00138],[@B55-medicina-55-00138]\]. In most of the studies, intervention was matched with a placebo \[[@B52-medicina-55-00138]\] or control interventions \[[@B43-medicina-55-00138],[@B45-medicina-55-00138],[@B46-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138],[@B53-medicina-55-00138],[@B54-medicina-55-00138],[@B55-medicina-55-00138]\]. The interventions were predominantly based on single consumption \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B45-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B50-medicina-55-00138],[@B54-medicina-55-00138]\], although two studies included short term (2--3 weeks) \[[@B53-medicina-55-00138],[@B55-medicina-55-00138]\] and two studies included long terms (6--10 weeks) \[[@B46-medicina-55-00138],[@B52-medicina-55-00138]\] treatments.

Interestingly, majority of the studies reported in this systematic literature review using the cladode as a food delivery product were from Frati and colleagues, where seven articles were included as a part of a separate trial. Firstly, a study by Frati et al. (1983a) demonstrated significant effects in reduction of GLU (*p* \< 0.01--0.05) and INS (*p* \< 0.01--0.02) post-prandial (0--3 h) with ingestion of 100g of broiled cladode in healthy males \[[@B45-medicina-55-00138]\]. When consumed for a longer period (10 days), a study by Frati et al. (1983b) \[[@B46-medicina-55-00138]\] indicated that consumption of the previously established quantity of cladode (100g) had significant reductions in fasted serum GLU (mean: 3.5 mmol/L) for T2DM participants (*n* = 7; *p* \< 0.01). Additionally, significant reductions were also reported in 'non-diabetic' participants (mean: 0.021 mmol/L *p* \< 0.05). In some cases, the participants of certain comparisons were not defined to the reported study groups but rather generalized as 'healthy' (*n* = 8) and 'obese' (*n* = 14; combined study groups) \[[@B46-medicina-55-00138]\]. A study that followed \[[@B48-medicina-55-00138]\] built on the single consumption investigations, where Frati et al. (1987) considered the effects of treatment and OGTT protocol interactions (cladode; cladode before dextrose bolus; cladode mixed with dextrose) to find significantly lower serum GLU (*p* \< 0.025; vs. water) at 60 and 180 min in healthy adults. No significant (*p* \> 0.05) effects were reported for serum INS between the treatments \[[@B48-medicina-55-00138]\]. Comparisons between single consumption of *Opuntia spp.* cladode and zucchini squash (500g) in T2DM participants (*n* = 48) were drawn on both GLU and INS parameters \[[@B47-medicina-55-00138]\]. Consumption of the broiled cladode resulted in significant reductions in serum GLU (1 h 8.5 ± 2.4%; 2 h 10.7 ± 1.4%; 3 h 17.6 ± 2.2% µU/mL; *p* \< 0.01--0.025) and INS (*p* \< 0.001; 1 h 22.5 ± 5.2%; 2 h 38.7 ± 6.3%; 3 50.2 ± 8.0%) \[[@B47-medicina-55-00138]\].

A study by Frati et al. (1990) \[[@B53-medicina-55-00138]\] continued to examine the effects of various cladode processing techniques \[[@B48-medicina-55-00138]\] (broiled, raw blended, broiled and blended, blended and broiled; 500 g) on fasted serums GLU in healthy participants. This study it was reported significant reductions in 120 and 190 min (*p* \< 0.001), although no significant (*p* \> 0.05) effects were observed between processing techniques \[[@B58-medicina-55-00138]\]. Investigations into the effects of cladode consumption with established volume and preparation on GLU and INS continued into T2DM participants, whereby the timing of sequential consumption was considered \[[@B44-medicina-55-00138]\]. In this study, there was a significant reduction (*p* \< 0.01) is fasting serum GLU in T2DM participants (2 h, 36.8 mg/dl; 4 h, 92 mg/dl; 6 h, 49 mg/dl) but not in healthy participants (*p* \> 0.05) \[[@B44-medicina-55-00138]\]. A study examining the effect of grilled cladode (500 g) in matched T2DM (*n* = 14) and healthy (*n* = 14) participants reported significant reductions in GLU (1 h: 1.19 ± 0.21 mM, *p* \< 0.005; 2 h: 1.57 ± 0.28 mM, *p* \< 0.005; 3 h: 2.26 ± 0.25 mM, *p* \< 0.001) and INS (*p* \<0.01; 1 h: 12.3 ± 15.9; 2 h: 3 h: 36.9 ± 10.8 pM; 56.4 ± 10.8 pM) in T2DM but not in a healthy group \[[@B43-medicina-55-00138]\]. These studies indicate that the consumption of cladode prepared in various ways (cooking procedures) significantly reduced blood GLU and INS levels in T2DM participants. Despite the significant reductions of GLU and INS with consumption of *Opuntia spp.* Cladode in T2DM participants, there is limited evidence to support the beneficial effects of the vegetable consumption in 'healthy' participants.

The remaining included articles considering cladode products in different forms such as an extract in a capsule \[[@B52-medicina-55-00138],[@B53-medicina-55-00138]\] a meal replacement \[[@B49-medicina-55-00138]\] and in combination with food \[[@B49-medicina-55-00138],[@B50-medicina-55-00138],[@B55-medicina-55-00138]\]. Castaneda-Andrad et al. (1997) \[[@B53-medicina-55-00138]\] reported that single dose cladode consumption, using a capsule (250 mg) significantly decreased serum GLU (319--220 mg/dL) in individuals living with T2DM compared with placebo (*p* \< 0.01). In addition, 6 weeks of supplementation of cladode extracts, provided as a capsule (*'NeOpuntia'*; 3 × 1.6 g), had no effect on glucose associated risk factors of Metabolic Syndrome in a female cohort \[[@B52-medicina-55-00138]\].

Cladode was also studied in combination with other foods, and it was provided in addition to foods incorporated or provided in a blinded form. A study by Lopez-Romero et al. (2014) \[[@B50-medicina-55-00138]\] conducted two trials within the same paper. In the first experiment, these authors investigated the glycemic responses to consumption of cladode powder (50 g) in healthy participants. The powder significantly lowered serum GLU (*p* \< 0.001) and produced a glycemic index score of 32.5 ± 4.0, and insulinemic index of 36.1 ± 6.1, upon ingestion. In the second experiment, the effect of cladode consumption in combination with various breakfasts (high carbohydrate; high soy protein) on serum GLU and INS in T2DM (*n* = 14) and healthy participants (*n* = 7) was investigated \[[@B50-medicina-55-00138]\]. The results showed that T2DM participants nopal consumption in combination with a high carbohydrate breakfast incurred significant decreases in serum GLU (30 min, 45 min and 1 h; *p* \< 0.01), GLU by Area Under the Curve (AUC reduction 287 ± 30 mmol/L; *p* \< 0.001), with no significant differences reported in serum INS \[[@B50-medicina-55-00138]\]. Significant differences were also observed between high carbohydrate and high soy protein breakfasts in GLU levels (*p* \< 0.001).

Lopez-Romero et al. (2014) reported no significant differences (*p* \> 0.05) in cladode powder ingested with a high-soy protein breakfast for parameters of GLU or INS in participants with T2DM, but there was a significant difference for INS AUC in healthy participants (decrease; *p* \< 0.01). A study by Bacardi-Gascon et al. (2007) \[[@B55-medicina-55-00138]\] investigated the cladode consumption by incorporating it into three meals; chilaquiles, burritos, and quesadillas with or without the cladode. Significant decreases in serum GLU (AUC) were apparent in all three meals (chilaquiles *p* = 0.018; burritos *p* = 0.025; quesadillas *p* = 0.019). A separate study by Guevare-Cruz et al. (2012) investigated the effects of a dietary pattern containing cladode among other ingredients to include chia seeds, oats, and soy protein against a less nutrient and bioactive dense placebo dietary pattern over a 2-month period \[[@B49-medicina-55-00138]\]. The mentioned dietary pattern was found to have a significant difference on AUC for INS (*p* \< 0.05) and diet-time interactions for INS as well (*p* \< 0.001). The GLU lowering effects of *Opuntia spp.* of the cladode are supported by literature; however, more evidence is recruited to make conclusions regarding INS.

### 3.2.3. Results of Combined or Unspecified *Opuntia spp*. Included Studies {#sec3dot2dot3-medicina-55-00138}

Combined *Opuntia spp*. plant products *(*[Table 3](#medicina-55-00138-t003){ref-type="table"}*)* were studied in both males and females, using the specifically-formulated tortillas and bars \[[@B51-medicina-55-00138]\] or commercially available 'OpundDia^©^' capsule dietary supplement, reported to contain 75% Cladode and 25% PP fruit extract. The *Opuntia spp.* products were investigated with control \[[@B36-medicina-55-00138],[@B51-medicina-55-00138]\] and cross-over \[[@B56-medicina-55-00138],[@B57-medicina-55-00138]\] designed trials in healthy \[[@B51-medicina-55-00138],[@B56-medicina-55-00138],[@B57-medicina-55-00138]\] and obese \[[@B36-medicina-55-00138]\] participants. Investigations into combined fruit and cladode products were consistent, where controls were established as placebo capsules \[[@B36-medicina-55-00138],[@B56-medicina-55-00138],[@B57-medicina-55-00138]\] or formulated products for investigation into single consumption models.

Investigations considering combined *Opuntia spp.* products considered the efficacy of the established products, with the exception of Guevera-Arauza et al. (2011) \[[@B51-medicina-55-00138]\], who developed several products. Acute and chronic effects of 'OpunDia^©^*'* in obese participants were investigated by Godard et al. (2010) \[[@B36-medicina-55-00138]\]. Acute trial (*n* = 29; 400 mg) indicated significant differences in serum GLU for time points 1, 2, and 3 h (*p* \< 0.05) between treatment and control (placebo capsules). Guevera-Arauza et al. (2011) \[[@B51-medicina-55-00138]\] concluded that the chronic supplementation of 'OpunDia*^©^*' over 16 weeks induced significant reductions in GLU both pre-and post-treatment (*p* \< 0.05) and placebo (*p* \< 0.05); and had no significant effects on INS \[[@B36-medicina-55-00138]\].

A study by Van Proeyen et al. (2012) \[[@B57-medicina-55-00138]\] investigated dose of 'OpunDia^©^' treatments (500 mg, 1000 mg, and 1500 mg) in combination with exercise interventions. Significant reductions in serum GLU were reported in pre-exercise (30 and 60 min; *p* \< 0.10--0.02) and post-exercise (60 min; *p* \< 0.04); and significantly increases INS during pre-exercise at 30 min (*p* \< 0.03), but not post-exercise \[[@B57-medicina-55-00138]\]. A study by Deldicque et al. (2013) \[[@B56-medicina-55-00138]\] continued in active participants, investigating the interaction between 'OpunDia^©^' in combination with amino acid, leucine, on INS stimulation in 'healthy' males following (endurance) exercise \[[@B56-medicina-55-00138]\]. In this study, there was a significant increase in INS with 'OpunDia^©^' (*p* \< 0.05) and in combination with Leucine (*p* \< 0.05); and significant decreases in GLU with 'OpunDia^©^' (*p* \< 0.05) but no other synergistic combinations.

A study by Guevera-Arauza et al. (2011) \[[@B51-medicina-55-00138]\] differed from other included combined *Opuntia spp.* in that the *Opuntia spp.* products were developed by investigators for the purpose of the study. The aim of this study was to determine the effect of the *Opuntia spp.* PP fruit and cladode in placebo and fortified food products including various bars and tortillas were tested on serum GLU. The results demonstrated a significant lowering effect (*p* \< 0.05; 4.43 mmol/L) on serum GLU in healthy participants upon product consumption.

4. Discussion {#sec4-medicina-55-00138}
=============

The *Opuntia spp.* cacti and its components have been reported to have 'anti-diabetic' or 'anti-hyperglycemic' properties \[[@B56-medicina-55-00138]\]. However, confusion exists within the literature between which *Opuntia spp.* components are responsible for the reported health effects \[[@B34-medicina-55-00138],[@B56-medicina-55-00138]\]. The *Opuntia spp.* cladode demonstrated significant positive health effects, indicating its potential as a functional food for potential short-term treatment of hyperglycemia in multiple sample participants.

Proposed mechanisms underlying how plant-based products may induce anti-hyperglycemic effects include individual or combined effects via the modulation of gastrointestinal absorption or regulation of INS secretion and sensitivity \[[@B56-medicina-55-00138]\]. The anti-hyperglycemic activities provided by plant-based products are diverse and are a result of a multiple contributing factors, including the presence of INS-like substances or 'factors' within the plant material \[[@B59-medicina-55-00138]\], upregulation of INS via β-cells \[[@B60-medicina-55-00138]\], increased insulin binding activity of receptors \[[@B60-medicina-55-00138]\], increase GLU metabolism \[[@B61-medicina-55-00138]\], high fiber content reducing the rate of absorption \[[@B62-medicina-55-00138]\], or potential regeneration of pancreatic cells \[[@B63-medicina-55-00138]\]. Various aspects of potential mechanisms are proposed following positive effects of specific *Opuntia spp.* products reported within this review. The findings of this review provide rationale for the use of *Opuntia spp.* products in applications such as incorporation into functional foods or nutraceuticals, given the additional substantial bioactive contents \[[@B18-medicina-55-00138],[@B19-medicina-55-00138],[@B20-medicina-55-00138],[@B21-medicina-55-00138],[@B22-medicina-55-00138],[@B23-medicina-55-00138],[@B24-medicina-55-00138],[@B25-medicina-55-00138],[@B26-medicina-55-00138],[@B27-medicina-55-00138],[@B28-medicina-55-00138],[@B29-medicina-55-00138],[@B30-medicina-55-00138],[@B31-medicina-55-00138]\].

4.1. Opuntia Ficus Indica Fruit {#sec4dot1-medicina-55-00138}
-------------------------------

Overall, the results of this systematic review suggest no significant effects on blood GLU \[[@B39-medicina-55-00138],[@B41-medicina-55-00138],[@B42-medicina-55-00138]\] and INS \[[@B42-medicina-55-00138]\], upon investigations into *Opuntia ssp.* PP fruit pulp \[[@B40-medicina-55-00138]\], pulp juice \[[@B39-medicina-55-00138]\], fruit peel \[[@B42-medicina-55-00138]\], and fruit extracts \[[@B41-medicina-55-00138]\]. The conclusions made regarding the results of this systematic review do consider the disagreements of significant differences in the reduction of GLU in hypercholesterolemic (*n* = 12) and hyperlipidemic (*n* = 12) sample participants; and INS in a hypercholesterolemic sample population (*n* = 12) \[[@B40-medicina-55-00138]\]. Although serum GLU was investigated in every included study regarding the PP fruit, it is important to recognize that INS was only studied in two of the four included fruit-based investigations \[[@B40-medicina-55-00138],[@B42-medicina-55-00138]\]. The conclusions drawn with respect to *Opuntia spp.* fruit are limited by high risk of bias with relation to selection, performance, and detection biases, but did show strengths in attribution and reporting bias.

Interestingly, the widely accepted associations of fiber as an anti-hyperglycemic effect \[[@B62-medicina-55-00138]\] were observed within the fruit-based studies included in this review. Anti-hyperglycemic effects are often reported in trial foods with a higher fiber content \[[@B62-medicina-55-00138]\], such as that expected of fruit flesh, unlike a majority of the investigations within this review. The included fruit-based studies investigating fruit products with substantially less fiber to include; juice \[[@B39-medicina-55-00138]\], peel \[[@B42-medicina-55-00138]\] and extracts \[[@B41-medicina-55-00138]\]. Future research should investigate the effects of PP fruit consumption regarding the INS-GLU relationship, with consideration of fiber. The results of this review do not encourage the prescription of PP fruit as an alternative medicine in treatment of hyperglycemia or associated conditions, until further evidence is developed.

4.2. Opuntia Ficus Indica Cladode Leaf {#sec4dot2-medicina-55-00138}
--------------------------------------

*Opuntia spp.* cladode consumption was associated with significantly lower serum GLU in healthy, obese \[[@B46-medicina-55-00138],[@B52-medicina-55-00138]\], and individuals with T2DM \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B46-medicina-55-00138],[@B47-medicina-55-00138],[@B50-medicina-55-00138],[@B53-medicina-55-00138],[@B54-medicina-55-00138],[@B55-medicina-55-00138]\]. Of the 12 included cladode-based investigations, 6 studies investigated INS responses \[[@B43-medicina-55-00138],[@B45-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138]\]. Conclusions regarding INS were not definitive, due to conflicting evidence \[[@B43-medicina-55-00138]\]. The majority of the sourced results indicated significant changes in serum INS on cladode consumption in healthy participants \[[@B45-medicina-55-00138]\] and individuals with T2DM \[[@B43-medicina-55-00138],[@B47-medicina-55-00138],[@B50-medicina-55-00138]\]. Conflicting evidence with respect to INS was seen in active and placebo diets including the cladode, as a whole product \[[@B50-medicina-55-00138]\] or as a powder (*n* = 67) \[[@B49-medicina-55-00138]\]; and studies investigating interactions between OGTT timing and cladode consumption, also indicated no significant effects \[[@B48-medicina-55-00138]\].

Consistent with previous hypotheses regarding GLU lowering mechanisms, the cladode leaf is reported to contain substantial amounts of fiber \[[@B34-medicina-55-00138],[@B62-medicina-55-00138]\]. Currently, due to the cladode's fiber content, it is utilized for the development of many food products and supplements, such as flours and fiber supplements \[[@B34-medicina-55-00138]\]. Future research should consider investigation into other potential mechanisms of action, and inter-relationships should be considered regarding the anti-hyperglycemic effects observed via consumption. In conclusion, the consumption of the cladode has noticeable effects of hyperglycemia; however, it should be recommended with caution and consideration of commonly-associated effects of food with high fiber content.

4.3. Opuntia Ficus Indica as Combined Fruit and Cladode Leaf {#sec4dot3-medicina-55-00138}
------------------------------------------------------------

Of the included articles within this review, four were identified as combined *Opuntia spp.* products; 'OpunDia^©^*'* capsule-based investigations \[[@B36-medicina-55-00138],[@B56-medicina-55-00138],[@B57-medicina-55-00138]\] and cladode-based food products \[[@B49-medicina-55-00138]\]. Both *Opuntia spp.* product investigations reported significant reduction in serum GLU. To our knowledge, the literature surrounding the effects of *Opuntia spp.* products on INS, were only studied using the 'OpunDia^©^' capsule; however, they reported conflicting results \[[@B36-medicina-55-00138],[@B56-medicina-55-00138],[@B57-medicina-55-00138]\].

The beneficial effects of the combined supplements (cladode and fruit) may be due to the greater cladode to fruit proportions within the 'OpunDia^©^' capsules. Noticeably, the studies examining the effects of the combined *Opuntia spp.* products do not control for the anti-hyperglycemic effects of fiber \[[@B62-medicina-55-00138]\]. A study by Deldicque et al. (2013) \[[@B56-medicina-55-00138]\] based investigation into 'OpunDia^©^' on the proposed mechanism of direct upregulation of INS by the *Opuntia ficus indica spp*, rather than indirect production of INS, in response to increased serum GLU. Multiple studies propose the direct insulinogenic actions of the *Opuntia spp.* products, described as acute and rapidly acting \[[@B56-medicina-55-00138]\], a result of upregulation of pancreatic β-cell INS secretion \[[@B56-medicina-55-00138],[@B57-medicina-55-00138]\]. Although, a study by Van Proeyen et al. (2012) \[[@B57-medicina-55-00138]\] proposed a dualist mechanism stemming from both GLU-induced and GLU-independent INS production of the combined *Opuntia spp.* product consumption. However, this finding was in a population undergoing an exercise intervention, in which they were characteristically more susceptible, or had improved INS sensitivity \[[@B57-medicina-55-00138]\]. The use and effectiveness of combined *Opuntia spp.* products are largely specific to the product, where further evidence is required on mechanisms of action before making conclusions regarding the effectiveness or advised supplementation.

5. Conclusions {#sec5-medicina-55-00138}
==============

The findings of this systematic literature review indicate that the cladode leaf and selection of combined *Opuntia spp.* products (typically containing a mix of cladode leaf and fruit) may have significant effects of serum GLU reduction. However, effects on INS were less consistent. The PP fruit was found to not have significant 'anti-hyperglycemic' effects, though the definitive evidence was conflicting. This suggests that there might be variability in the potential anti-hyperglycemic effects of different plant parts of *Opuntia spp*., which warrants further investigation. Study characteristics including design, exposure, quantity, and participants, as well as the treatment product and compositions, varied extensively, limiting the conclusions within this review. Future research should investigate the serum glucose-insulin relationships within consumption-based investigation and the inter-relationships within the proposed mechanisms of action, ideally following standardized and reproducible methodologies.
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medicina-55-00138-t001_Table 1

###### 

The Summary of the effect of *Opuntia spp*. fruit consumption on blood glucose levels and insulin in human trials \[[@B39-medicina-55-00138],[@B40-medicina-55-00138],[@B41-medicina-55-00138],[@B42-medicina-55-00138]\].

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)                                         Participant, Sample Size                              Aim                                                                                                                                                                                     Intervention                                                                                                                                                               Relevant Outcome                                                 Results (C vs. T))
  ----------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Khouloud et al. (2016) \[[@B39-medicina-55-00138]\]   Healthy M (*n* = 22)\                                 Effect of flavonoid standardized PP fruit (*Opuntia ficus indica*; purple; peeled*)* juice consumption on cardiovascular, oxidative stress and biochemical parameters during exercise   Duration: 2 w\                                                                                                                                                             Fasted\                                                          Before vs. After Exercise:\
                                                        T (*n* = 11)\                                                                                                                                                                                                                                 T: 3 × day 30 mL/day PP juice;\                                                                                                                                            GLU                                                              ↑ GLU (*p* = 0.01) for both\
                                                        Age: 20.91 ± 1.22 years\                                                                                                                                                                                                                      C*:* No antioxidants: 150 mL/day\                                                                                                                                                                                                           Treatment and Control groups\
                                                        C (*n =* 11)\                                                                                                                                                                                                                                 RCT                                                                                                                                                                                                                                         No difference between groups were reported
                                                        Age: 21.00 ± 0.84 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Wolfram et al. (2002) \[[@B40-medicina-55-00138]\]    M (*n* = 24)\                                         The effect of PP (*Opuntia Robusta)* pulp pectin on GLU and lipid metabolism                                                                                                            Duration: 16 w\                                                                                                                                                            Fasted (14 hrs.):\                                               ↓ GLU between phase 1 and 2 (*p* \< 0.005) for both groups 1 and 2\
                                                        Age: 37--55 y (45 ± 4.7 years)\                                                                                                                                                                                                               Pre-running phase:\                                                                                                                                                        GLU\                                                             ↓ INS between phase 1 and 2 for group 1 (*p* \< 0.005)\
                                                        Group 1: (*n* = 12)\                                                                                                                                                                                                                          Diet: 7506 kJ (625 kJ 50% fibers and 50% CHO; 8 w)\                                                                                                                        INS                                                              INS group 2 = NS (*p* \> 0.05)
                                                        'Hypercholesterolemic'\                                                                                                                                                                                                                       Phase 2: Replaced diet fiber and CHO with fresh 250g/day of PP pulp (8 weeks)\                                                                                                                                                              
                                                        Group 2: (*n* = 12)\                                                                                                                                                                                                                          Parallel CT                                                                                                                                                                                                                                 
                                                        'Hyperlipidemic'                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Pimienta et al. (2008) \[[@B42-medicina-55-00138]\]   Phase 1:\                                             The effects of yellow PP fruit peel on health males (single consumption) and diabetic females(Chronic; 5 weeks)                                                                         Phase 1:\                                                                                                                                                                  OGTT (12 h fasted)\                                              Phase 1:\
                                                        'Healthy' M (*n* = 14)\                                                                                                                                                                                                                       Single consumption\                                                                                                                                                        Time −20, 0, 20, 30, 60, 80, 100, 120, 140, 160, 190, 200 min\   ↓ GLU: treatment vs. control (40 min) (*p* \< 0.05), all other time points NS (*p* \> 0.05)\
                                                        Age: 22.4 ± 3.2 years\                                                                                                                                                                                                                        *Treatment:* 250 g fruit peel and GLU solution\                                                                                                                            Phase 1 and 2:\                                                  ↑ INS treatment NS (*p* \> 0.05)\
                                                        Phase 2:\                                                                                                                                                                                                                                     *Control:* 75 g GLU (solution)\                                                                                                                                            GLU\                                                             Phase 2:\
                                                        'T2DM participants'\                                                                                                                                                                                                                          Control trial\                                                                                                                                                             INS                                                              INS 'healthy' and diabetics NS (*p* \> 0.05)\
                                                        F (*n =* 10)\                                                                                                                                                                                                                                 Phase 2:\                                                                                                                                                                                                                                   GLU: diabetics NS (*p* \> 0.05)
                                                        Age: 42.4 ± 3.3 years                                                                                                                                                                                                                         Duration: 5 w\                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                      Fasted; 3 × 50 g PP peel/week\                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                      *Control:* Baseline measurements\                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                      Control Trial                                                                                                                                                                                                                               

  Wiese et al. (2004) \[[@B41-medicina-55-00138]\]      'Healthy M&F with history of at least one hangover\   The effect of *Opuntia ficus indica* PP fruit extract in reducing symptoms of severity from alcohol hangover                                                                            Length: Single consumption\                                                                                                                                                GLU                                                              Baseline VS. placebo: NS (*p* \> 0.05)\
                                                        (*n* = 55)\                                                                                                                                                                                                                                   *Induced hangover:* Consumption of 1.75 g of alcohol/kg (Low: vodka, gin, rum; high: bourbon, scotch, tequila) with standard meal (cheeseburger, French fries and soda)\                                                                    Placebo VS. treatment: NS (*p* \> 0.05)
                                                        M (*n* = 37)\                                                                                                                                                                                                                                 Treatment: 2× capsule of *Opuntia ficus indica* PP fruit extract\                                                                                                                                                                           
                                                        F (*n* = 18)\                                                                                                                                                                                                                                 Placebo: 2× capsule\                                                                                                                                                                                                                        
                                                        Age: 21--25 years                                                                                                                                                                                                                             2 w washout\                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                      Randomized Control Cross-Over Trial                                                                                                                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: Body Mass Index; PP: Prickly Pear; YYIRT: Yo-Yo Intermitted Recovery Test; GLU: Blood Glucose; NS: Not Significant; NR: Not Reported; CHO: Carbohydrate; h-hours; INS: Serum insulin; ↓: Decrease; ↑: Increase.

medicina-55-00138-t002_Table 2

###### 

The summary of the effect of *Opuntia spp*. cladode consumption on blood glucose and insulin in human trials \[[@B43-medicina-55-00138],[@B44-medicina-55-00138],[@B45-medicina-55-00138],[@B46-medicina-55-00138],[@B47-medicina-55-00138],[@B48-medicina-55-00138],[@B49-medicina-55-00138],[@B50-medicina-55-00138],[@B51-medicina-55-00138],[@B52-medicina-55-00138],[@B53-medicina-55-00138],[@B54-medicina-55-00138],[@B55-medicina-55-00138]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)                                                  Participant, Sample Size                                               Aim                                                                                                           Intervention                                                                                                                                                                                                                                                                                                       Relevant Outcomes                                                           Results (Treatment vs. Placebo)
  -------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  **Acute Results**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Frati et al. (1983) \[[@B45-medicina-55-00138]\]               'Healthy' Males (*n* = 5)\                                             The effect of 'Nopal' (CLD; *Opuntia streptacantha)* consumption on OGTT, on GLU and INS in healthy males     Length: Single consumption\                                                                                                                                                                                                                                                                                        GLU (mg/dl)\                                                                GLU: ↓ after meal CLD consumption\
                                                                 Age: 28--35 years                                                                                                                                                                    Treatment:\                                                                                                                                                                                                                                                                                                        INS (µU/mL)\                                                                0 min (*p* \< 0.01), 60 min (*p* \< 0.05), 120 min (*p* \< 0.05), 180 min (*p* \< 0.01)\
                                                                                                                                                                                                                                                      (1)75 g GLU(2)75 g GLU + 100 g broiled CLD stems (20 min before OGTT)\                                                                                                                                                                                                                                             Time: 0, 60, 120, 180 min                                                   INS: ↓ after meal CLD consumption;\
                                                                                                                                                                                                                                                      Control trial                                                                                                                                                                                                                                                                                                                                                                                  0 min (*p* \< 0.01), 60 min (*p* \< 0.01), 120 min (*p* \< 0.01), 180 min (*p* \< 0.02)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     T2DM

  Frati et al. (1987) \[[@B48-medicina-55-00138]\]               'Healthy' Adults\                                                      The effect of CLD *(Opuntia sp.)* consumption on blood GLU and INS response, to dextrose in OGTT              Length: Single Consumption\                                                                                                                                                                                                                                                                                        GLU\                                                                        CLD consumption on GLU and INS = NS (*p* \> 0.05)\
                                                                 (*n* = 16)\                                                                                                                                                                          Group 1: 12 h fasted + treatment\                                                                                                                                                                                                                                                                                  INS\                                                                        GLU: NS (*p* \> 0.05); except for: Group 1 vs Group 2 (CLD vs. OGTT+CLD): 60 min; 180 min (*p* \< 0.025)
                                                                 Group 1: (*n* = 5)\                                                                                                                                                                  Group 2: OGTT (25 g GLU), CLD given after time 0, before GLU load\                                                                                                                                                                                                                                                 Blood collection:\                                                          
                                                                 Group 2: (*n* = 6)\                                                                                                                                                                  Group 3: OGTT (25 g GLU) + treatment\                                                                                                                                                                                                                                                                              Group 1 and 3: 0, 30, 60, 120, 180 min\                                     
                                                                 Group 3: *(n* = 5)                                                                                                                                                                   CLD Treatment: 100 g on CLD, ground and mixed with 100 g of water\                                                                                                                                                                                                                                                 Group 2: 0, 5, 15, 30, 60, 120 min                                          
                                                                                                                                                                                                                                                      Controls in each group:\                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                      12 h fasting:\                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                      OGTT + Nopal load\                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                      OGTT + 200 mL water                                                                                                                                                                                                                                                                                                                                                                            

  Frati et al. (1990) \[[@B54-medicina-55-00138]\]               T2DM\                                                                  The effect of *Opuntia ficus indica* on hyperglycemia (CLD) in T2DM                                           Length: single consumption\                                                                                                                                                                                                                                                                                        Fasted (12 h) blood: 40, 60, 120, 180 min\                                  ↓ GLU at 120 min and 190 min (VS. control (baseline); *p* \< 0.01)\
                                                                 (*n* = 8; 2 Males; 6 Females)\                                                                                                                                                       Treatments: (500 g)\                                                                                                                                                                                                                                                                                               GLU                                                                         NS differences between heated and unheated (*p* \> 0.05)
                                                                 Age: 45--68 years\                                                                                                                                                                   (1)Entire Broiled CLD(2)Blended and broiled CLD(3)Blended CLD(4)Blended and heated (60 °C) CLD\                                                                                                                                                                                                                                                                                                
                                                                 (Mean: 55 years)                                                                                                                                                                     Cross-over trial                                                                                                                                                                                                                                                                                                                                                                               

  Frati et al. (1991) \[[@B44-medicina-55-00138]\]               Group 1:\                                                              The effect of two sequential doses of *Opuntia streptacantha* stems blood GLU and INS                         Length: single consumption\                                                                                                                                                                                                                                                                                        Blood: 0,2,4 and 6 h\                                                       Test A vs Test B:\
                                                                 (*n* = 8; 2 Males; 5 Females)\                                                                                                                                                       Treatment:\                                                                                                                                                                                                                                                                                                        GLU                                                                         ↓GLU: Group 1 first ingestion at 2, 4 and 6 h (*p* \< 0.001)\
                                                                 T2DM\                                                                                                                                                                                500 g broiled cladode\                                                                                                                                                                                                                                                                                                                                                                         NS: 'Healthy' participants (*p* \> 0.05)
                                                                 Age:36--65 years\                                                                                                                                                                    Test A:\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                 (50 years)\                                                                                                                                                                          Ingestion at time 0 h, 2 h; 300 mL water at 4 h\                                                                                                                                                                                                                                                                                                                                               
                                                                 Group 2:\                                                                                                                                                                            Test B:\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                 (*n* = 6; 3 Females; 3 Male)\                                                                                                                                                        Ingestion at time 0 h,\                                                                                                                                                                                                                                                                                                                                                                        
                                                                 'Healthy' volunteers\                                                                                                                                                                300 mL water at 2 h, 4 h\                                                                                                                                                                                                                                                                                                                                                                      
                                                                 Age: 15--45 years\                                                                                                                                                                   Test C (control):\                                                                                                                                                                                                                                                                                                                                                                             
                                                                 (25 years)                                                                                                                                                                           300mL water at 2 h, 4 h\                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                      Control-trial                                                                                                                                                                                                                                                                                                                                                                                  

  Frati et al. (1991) \[[@B43-medicina-55-00138]\]               Group 1: T2DM\                                                         The effect of 'Nopal' (CLD; *Opuntia streptacantha)* consumption on blood and GLU of T2DM                     Length: Single consumption\                                                                                                                                                                                                                                                                                        GLU\                                                                        GLU:\
                                                                 (*n =*14; 9 Males, 5 Females)\                                                                                                                                                       Group 1 and 2 treatments: (fasted) 500g grilled CLD *(Opuntia streptacantha);* or 400 mL Water\                                                                                                                                                                                                                    INS                                                                         ↓ in T2DM (Vs Control) (p *\<* 0.005, 60 min; *p* \< 0.005 120; p\<0.001 180 min)\
                                                                 Age: 32--56 years\                                                                                                                                                                   Randomized control trial                                                                                                                                                                                                                                                                                                                                                                       'Healthy'- NS (*p* \> 0.05)\
                                                                 (Mean: 43.4 years);\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                INS: (*n* = 7, each Group)\
                                                                 Group 2: 'Healthy' (*n* = 14;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ↓- T2DM (vs. control) (*p* \< 0.001; 120 min, 180 min)\
                                                                 9 Males; 5 Females)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                'Healthy': NS
                                                                 Age: 23--51 years\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                 (Mean: 32.7 years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Frati et al. (1988) \[[@B47-medicina-55-00138]\]               T2DM (*n* = 16)\                                                       The effect of CLD *(Opuntia streptacantha)* consumption on T2DM                                               Length: Single consumption\                                                                                                                                                                                                                                                                                        GLU\                                                                        GLU: ↓ (vs. basal; *p* \< 0.001)\
                                                                 Group 1: (*n* = 16; 9 Males, 7 Females)\                                                                                                                                             Hyperglycemic agents discontinued 72 h before trial.\                                                                                                                                                                                                                                                              INS\                                                                        *Group 1* vs. *2:* ↓ 60 min (*p*\< 0.025); 120 min (*p* \< 0.001); 180 min (*p* \< 0.001)\
                                                                 Age: 32--67 years,\                                                                                                                                                                  Treatment:\                                                                                                                                                                                                                                                                                                        (fasted; 12 h)\                                                             Group 2: No change\
                                                                 Mean: 48.3±11.4 years (*n* = 12 received sulfonylureas)\                                                                                                                             Group 1: 500 g of Broiled CLD\                                                                                                                                                                                                                                                                                     Time: 0, 60, 120, 180 min.                                                  Group 3: NS (*p* \> 0.05)\
                                                                 Group 2: (*n* = 10; 6 Males; 4 Females)\                                                                                                                                             Group 2: 300 mL water\                                                                                                                                                                                                                                                                                                                                                                         INS: ↓ Serum INS\
                                                                 Age: 31--67 years\                                                                                                                                                                   Group 3: 500 g of Broiled Squash (zucchini)\                                                                                                                                                                                                                                                                                                                                                   Group 1 vs. 2: ↓ 120 min, 180 min (*p* \< 0.001)\
                                                                 Mean: 46.2 ± 10.8 y; (*n* = 10 received sulfonylureas)\                                                                                                                              Randomized control-trial                                                                                                                                                                                                                                                                                                                                                                       Group 3: NS (*p* \> 0.05)
                                                                 Group 3: (*n* = 6; 4 Males; 2 Females)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                 Age: 33--66 years\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                 Mean: 48 ± 11.7 years (*n* = 4 received sulfonylureas)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Lopez-Romero et al. (2014) \[[@B50-medicina-55-00138]\]        Study 1:\                                                              Determine glycemic index of Nopal and Effect of nopal consumption on blood GLU                                Fasted (12 h)\                                                                                                                                                                                                                                                                                                     GLU\                                                                        Study 1:\
                                                                 'Healthy' (*n* = 7; 3 Males, 4 Females)\                                                                                                                                             Treatment: 150 g steamed Nopal\                                                                                                                                                                                                                                                                                    INS\                                                                        *Nopal ingestion (vs. GLU)* ↓ AUC GLU (*p* \< 0.001)\
                                                                 Age: 26.3 ± 1.2 years;\                                                                                                                                                              Study 1:\                                                                                                                                                                                                                                                                                                          Study 1:\                                                                   *Glycemic index on Nopal*: 32.5 ± 4.0\
                                                                 BMI: 23.5 ± 0.8 kg/m^2^Study 2:\                                                                                                                                                     Length: Single consumption\                                                                                                                                                                                                                                                                                        Blood (capillary and Venous)\                                               *Nopal ingestion (vs. GLU)* ↓ AUC INS (*p* \< 0.05)\
                                                                 Group 1: T2DM (*n* = 14; 4 Males; 10 Females)\                                                                                                                                       Dried nopal (CLD): 24.8% CHO; 32.2% insoluble fiber; 4.8% soluble fiber; \<1.9% fat; 15.4% PRO.\                                                                                                                                                                                                                   15, 30, 45, 60, 90 and 120 min\                                             *Insulinemic index of Nopal*: 36.1 ± 6.1\
                                                                 Age: 40--60 years\                                                                                                                                                                   50 g of Nopal vs. 50 g GLU\                                                                                                                                                                                                                                                                                        Study 2:\                                                                   Study 2:\
                                                                 (Mean 48 ± 2.1 years);\                                                                                                                                                              Control trial\                                                                                                                                                                                                                                                                                                     Blood (capillary and Venous)\                                               *High CHO Breakfast + Nopal*= ↓ GLU at 30 min (*p* \< 0.05), 45 min (*p* \< 0.01), 60 min (*p* \< 0.01);\
                                                                 BMI: \<30 kg/m^2^\                                                                                                                                                                   Study 2:\                                                                                                                                                                                                                                                                                                          15, 30, 45, 60, 90, 120 and 150 min                                         ↓ AUC GLU (*p* \< 0.001).\
                                                                 (Mean 28.9 ± 1 kg/m^2^)\                                                                                                                                                             Length: Single consumption\                                                                                                                                                                                                                                                                                                                                                                    ↓ AUC of INS (*p* \< 0.05) in diabetes patients\
                                                                 Group 2: 'Healthy'\                                                                                                                                                                  *High CHO breakfast*: 300 kcal; 89% CHO; 6% PRO; 5% fat (240 mL apple juice, 55.6 g white bread, 21 g strawberry jam)\                                                                                                                                                                                                                                                                         *High soy protein breakfast:* ↓GLU (*p* \< 0.001) regardless of group; Nopal GLU was NS (*p* \> 0.05)\
                                                                 (*n* = 7; 4 Males; 3 Females)\                                                                                                                                                       *High Soy Protein Breakfast*: 344 kcal; 42.2% CHO, 40.7% PRO; 16.9% fat (61.5 g soy hamburger, 230 mL soymilk beverage).\                                                                                                                                                                                                                                                                      Nopal INS was NS (*p* \> 0.05)
                                                                 Age: 25--54 years\                                                                                                                                                                   Washout period: 1 week\                                                                                                                                                                                                                                                                                                                                                                        
                                                                 (Mean 21.1 ± 1.2 years)\                                                                                                                                                             Cross-over trial                                                                                                                                                                                                                                                                                                                                                                               
                                                                 BMI: \<25 kg/m^2^\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                 (Mean: 22.2 ± 0.6 kg/m^2^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Castaneda-Andrade et al. (1997) \[[@B53-medicina-55-00138]\]   T2DM (*n* =8;\                                                         The effect of *Opuntia streptacantha* on hyperglycemia (CLD) in T2DM                                          Length:\                                                                                                                                                                                                                                                                                                           12 h fasted blood (0, 60, 120, 180 min)\                                    ↓ GLU (60 + min) both groups;\
                                                                 2 Males; 6 Females)\                                                                                                                                                                 Single consumption\                                                                                                                                                                                                                                                                                                GLU\                                                                        ↓ GLU (basal vs. 180 min) (*p* \< 0.001) for both groups
                                                                 Age: 58.4 years\                                                                                                                                                                     Treatment:\                                                                                                                                                                                                                                                                                                        INS                                                                         
                                                                 (Range: 48.9--67.8 years)                                                                                                                                                            Group A: 250 mg CLD capsule\                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                      Group B: placebo capsules\                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                      Randomized cross-over trial                                                                                                                                                                                                                                                                                                                                                                    

  **Long-term results**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Frati et al. (1983) \[[@B46-medicina-55-00138]\]               11 Males; 18 Females (*n* =29)\                                        The effect of 'Nopal' (CLD; *(Opuntia streptacantha)* consumption on serum lipids, glycemia and body weight   Length: 10 days\                                                                                                                                                                                                                                                                                                   GLU (m mol/DI)\                                                             GLU: ↓ (vs. fasting blood GLU) T2DM (*p* \< 0.001), 'non-T2DM' (*p* \< 0.05)
                                                                 'Healthy': (*n* = 8)\                                                                                                                                                                Treatment:\                                                                                                                                                                                                                                                                                                        (Fasting; Pre- VS. Post-treatment)                                          
                                                                 '0--8% overweight; Mean 8%'\                                                                                                                                                         (1)Regular diet(2)Regular diet + 100 g broiled CLD before meals, 3 × day; 10 days\                                                                                                                                                                                                                                                                                                             
                                                                 Obese: (*n* = 14)\                                                                                                                                                                   Total per day: 300 g CLD\                                                                                                                                                                                                                                                                                                                                                                      
                                                                 '18--70% overweight'; Mean 35%\                                                                                                                                                      Total: 3000 g/10 days\                                                                                                                                                                                                                                                                                                                                                                         
                                                                 T2DM: (*n* = 7); 1--5% overweight; received tolbutamide during trial                                                                                                                 Control trial                                                                                                                                                                                                                                                                                                                                                                                  

  Guevare-Cruz et al. (2012) \[[@B49-medicina-55-00138]\]        'Healthy' (*n* = 67)\                                                  The effect of dietary pattern on biochemical markers                                                          2 weeks prior: Reduced energy diet, low-saturated fay and low-cholesterol diet. (15 × eating plans: 50--60% CHO; 15% PRO; 25--35% FAT; \<7% saturated fat, \<200mg/d cholesterol, 20--30 g/d fiber.)\                                                                                                              Pre/Post intervention\                                                      No change in either treatment group for GLU\
                                                                 Age: 20--60 years\                                                                                                                                                                   Treatment:\                                                                                                                                                                                                                                                                                                        OGTT: 75 g GLU (120 min)\                                                   INS\
                                                                 BMI: 25--39.9 kg/m^2^                                                                                                                                                                Length: 2 months\                                                                                                                                                                                                                                                                                                  GLU\                                                                        AUG:\
                                                                                                                                                                                                                                                      Group 1: Controlled Dietary Pattern\                                                                                                                                                                                                                                                                               INS                                                                         No difference in OGTT.\
                                                                                                                                                                                                                                                      Group 2: Placebo\                                                                                                                                                                                                                                                                                                                                                                              ↑ INS in OGTT of Dietary Pattern (*p* \< 0.05)\
                                                                                                                                                                                                                                                      *Dietary Pattern:* 100 g nopal (CLD), 4 g chia seeds, 22 g oats, 32g soy bean proteins, 0.02 g sweetener ('Splenda'), 1 g flavoring\                                                                                                                                                                                                                                                           ↑ Significant diet and time interaction between pre/post diet intervention on INS (*p* \< 0.01)
                                                                                                                                                                                                                                                      *Placebo:* 30 g calcium caseinate, 30 g maltodextrin, 0.02 g sweetener ('Splenda'), 1 g flavoring.\                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                      Single-center, randomized, placebo-controlled, double-blind, parallel-art study                                                                                                                                                                                                                                                                                                                

  Linares et al. (2007) \[[@B52-medicina-55-00138]\]             Females (*n* = 59)\                                                                                                                                                                  Length: 6 weeks- with 'balanced diet' (2000 kcal; 38% Fats; 17% PRO; 45% CHO) and 30 min of physical activity/day.\                                                                                                                                                                                                Prevalence of Fasting GLU (\>0.95 g/L)                                      GLU:\
                                                                 Age: \<35 years (10.29%)\                                                                                                                                                            Treatment: 3 × 1.6 g 'NeOpuntia^©^' capsules, after meal/day with water.\                                                                                                                                                                                                                                                                                                                      Treatment group remained the same during study period (*n =* 15).\
                                                                 35--45 years (27.94%)\                                                                                                                                                               Control: 3 × Placebo Capsule\                                                                                                                                                                                                                                                                                                                                                                  ↑ in placebo group (*n* = 20→22).
                                                                 45--55 years (41.18%)\                                                                                                                                                               Monocentric, randomized, double-blind, placebo-controlled study                                                                                                                                                                                                                                                                                                                                
                                                                 \>55 years (20.59%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                 BMI: 25--40 kg/m^2^\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                 Placebo group: *n* = 33\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                 Treatment group: *n* = 35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Bacardi-Gascon et al. (2007) \[[@B55-medicina-55-00138]\]      T2DM\                                                                  Post-prandial glycemic response to nopal (CLD)                                                                Length: 3 weeks\                                                                                                                                                                                                                                                                                                   Fasted Baseline: 0, 50g of white bread at 15, 30, 45, 60, 90 and 120 min\   ↓ GLU over all; (*p* = 0.029)\
                                                                 (*n* = 36)\                                                                                                                                                                          Treatment: 1 × week/3 weeks (fasted)\                                                                                                                                                                                                                                                                              GLU                                                                         Group 1:\
                                                                 Age: 47--72 years\                                                                                                                                                                   (1)Chilaquiles (corn tortilla, vegetable oil, tomato sauce, cheese, pinto beans) (with vs with-out CLD)(2)Burrito (scrambled egg, tomato, onion, vegetable oil, flour tortilla, pinto beans) (with and without-CLD)(3)Quesadillas (flour tortilla, low fat cheese, avocado, pinto beans) (with and without CLD)\                                                                               ↓ AUC (with vs. without; *p* = 0.013)\
                                                                 GLU: 8.0 ± 2 mmol/L\                                                                                                                                                                 7-day washout periods\                                                                                                                                                                                                                                                                                                                                                                         ↓ Glycemic index white bread and GLU (*p* = 0.018)\
                                                                 BMI: 24.86 ± 3.76 kg/m^2^\                                                                                                                                                           Control: Chilaquiles, Burrito and Quesadillas without cladode\                                                                                                                                                                                                                                                                                                                                 Group 2:\
                                                                 Group 1: *n* = 11\                                                                                                                                                                   Placebo-controlled Cross-over trial                                                                                                                                                                                                                                                                                                                                                            ↓ AUC (with vs. without CLD; *p* = 0.011)\
                                                                 Group 2: *n* = 9\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↓ Glycemic index of white bread and GLU (*p* = 0.025)\
                                                                 Group 3: *n* = 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Group 3:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ↓ AUC (with vs. without CLD; *p* = 0.019)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ↓ Glycemic index of white bread and GLU (*p* = 0.027; *p* =0.025)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NNIDM: Non-Insulin Dependent Diabetes Mellitus; BMI: Body Mass Index; CLD: Cladode; GLU: Blood Glucose; INS: Serum insulin; NS: Not Significant; h-hours; OGTT: Oral Glucose Tolerance Test; AUC: Area Under the Curve ↓: Decrease; ↑: Increase.
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###### 

The summary of the effect of combined or unidentified *Opuntia spp*. fruit and cladode consumption on blood glucose and insulin in human trials \[[@B36-medicina-55-00138],[@B51-medicina-55-00138],[@B56-medicina-55-00138],[@B57-medicina-55-00138]\].

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)                                               Participant, Sample Size                        Aim                                                                                      Intervention                                                                                                                                                Relevant Outcomes                                            Results (Treatment vs Placebo)
  ----------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------
  **Acute Results**                                                                                                                                                                                                                                                                                                                                                                                                             

  Deldicque et al. (2013) \[[@B56-medicina-55-00138]\]        'Healthy'\                                      Effect of:\                                                                              Length: Single Consumption\                                                                                                                                 OGTT\                                                        OGTT:\
                                                              Males (*n* = 11)\                               (1)'OpunDia'(2)'OpunDia' + Leu (Leu)\                                                    Fasted; post-30 min endurance exercise (70% VO~2~); 75 g of GLU with treatment at: 0 min and 60 min.\                                                       (2 h)\                                                       INS higher with 'OpunDia+Leu', after 60 min (vs. Placebo)\
                                                              Age: 21.1 ± 0.9 years\                          Supplementation on INS stimulation                                                       Treatment:\                                                                                                                                                 INS\                                                         INS:\
                                                              Weight: 74.4 ± 4.2 kg                                                                                                                    (1)Placebo 'LUVOS Heilerde'(2)1000 mg 'OpunDia^©^'(3)3 g Leu(4)1000 mg 'OpunDia^©^' + 3 g Leu\                                                              GLU                                                          OpunDia+Leu ↑40% at 2 h (vs. placebo) (*p* \< 0.05)\
                                                                                                                                                                                                       *1-week wash-out*\                                                                                                                                                                                                       OpunDia ↑ 2 h (vs. Placebo) (*p* \< 0.05)\
                                                                                                                                                                                                       Randomized double-blind cross-over study                                                                                                                                                                                 AUC: OpunDia ↑ (*p* = 0.06)\
                                                                                                                                                                                                                                                                                                                                                                                                                                AUC: OpunDia+Leu (*p* \< 0.05)\
                                                                                                                                                                                                                                                                                                                                                                                                                                Leu-no effect\
                                                                                                                                                                                                                                                                                                                                                                                                                                GLU:\
                                                                                                                                                                                                                                                                                                                                                                                                                                OpunDia ↓GLU by 7% (90 min), 15% (120 min) (vs. placebo; *p* \< 0.05)\
                                                                                                                                                                                                                                                                                                                                                                                                                                AUC: ↓ OpunDia vs. placebo (*p* \< 0.05)

  Van Proeyen et al. (2012) \[[@B57-medicina-55-00138]\]      'Healthy'\                                      The effect of 'OpunDia' supplementation on blood GLU and INS before and after exercise   Length: Single consumption\                                                                                                                                 30, 60, 90, 120 min capillary and Venous blood collection\   Pre-exercise:\
                                                              Males (*n =* 6)\                                                                                                                         *Standardized Dinner:* 860 kcal; 73% CHO, 14% fat, 13% PRO); 12 h Fast\                                                                                     GLU\                                                         ↓GLU: 30 min (*p* \< 0.10), 60 min (*p* \< 0.02). 60 + min = NS (*p* \> 0.05).\
                                                              Age: 21.0 ± 1.6 years; Weight: 78.1 ± 6.0 kg;                                                                                            *Exercise:* 30 min submaximal endurance\                                                                                                                    INS                                                          ↓GLU AUC (*p* \< 0.03)\
                                                                                                                                                                                                       Treatment: 500 mg, 1000 mg, 1500 mg 'OpunDia'Placebo 'LUVOS Heilerde'\                                                                                                                                                   ↑ INS (*p* \< 0.01).\
                                                                                                                                                                                                       *Pre- and post- exercise:*\                                                                                                                                                                                              ↑ INS: 30 min (*p* \< 0.03)\
                                                                                                                                                                                                       *OGTT* (2 h)-75 g GLU\                                                                                                                                                                                                   INS AUC = NS (*p* \> 0.05)\
                                                                                                                                                                                                       \* Post-exercise OGTT, additional bolus at 60 min\                                                                                                                                                                       Post-exercise:\
                                                                                                                                                                                                       *2-week washout period*\                                                                                                                                                                                                 ↓ GLU: 60 min (*p* \< 0.04)\
                                                                                                                                                                                                       Double-bind Placebo-controlled crossover study                                                                                                                                                                           ↓ GLU AUC (*p* \< 0.03)\
                                                                                                                                                                                                                                                                                                                                                                                                                                INS = NS (*p* \> 0.05)

  Godard et al. (2010) \[[@B36-medicina-55-00138]\]           Obese (*n* = 29; Males and Females)\            Determine the acute and chronic effects of 'OpunDia'                                     Length: Single consumption\                                                                                                                                 Acute:\                                                      Acute:\
                                                              BMI: 30--35 kg/m^2^\                                                                                                                     Treatment: 200 mg 'OpunDia'\                                                                                                                                GLU\                                                         'OpunDia' vs Fasted: 60, 90 and 120 min (*p* \< 0.05)\
                                                              Age: 20--50 years\                                                                                                                       Placebo: 200 mg microcrystalline cellulose\                                                                                                                 Blood time: 0, 30, 60, 90, 120 min\                          Chronic:\
                                                              Acute: *n* = 29\                                                                                                                         Acute trial:\                                                                                                                                               Chronic:\                                                    GLU:\
                                                              Chronic:\                                                                                                                                400 mg 'OpunDia' 30 min prior to 75 g GLU (OGTT);\                                                                                                          OGTT\                                                        Pre/Post- 'OpunDia': ↓ 60, 90 and 120 min (*p* \< 0.05)\
                                                              Treatment: *n* = 15\                                                                                                                     Chronic trial:\                                                                                                                                             GLU\                                                         Pre/Post Placebo: ↓ 60, 90 min (*p* \< 0.05)\
                                                              Control: *n* = 14                                                                                                                        Length: 16 weeks\                                                                                                                                           INS                                                          INS:\
                                                                                                                                                                                                       2 × Treatment (200 mg) or Placebo\                                                                                                                                                                                       Pre/Post 'OpunDia': NS (*p* \> 0.05)\
                                                                                                                                                                                                       Randomized, Double-blind, placebo-controlled trial                                                                                                                                                                       Pre/Post Placebo: NS (*p* \> 0.05)

  **Long-term results**                                                                                                                                                                                                                                                                                                                                                                                                         

  Guevara-Arauza et al. (2011) \[[@B51-medicina-55-00138]\]   'Healthy' (*n* = 28; 12 Males, 16 Females)      To determine bio-functional effects of nopal (CLD) and PP fruit products                 Length: 3 weeks\                                                                                                                                            Fasted (8 h) blood samples;                                  Tortilla VS. control:\
                                                                                                                                                                                                       Treatment: Supplement diet with 40 g Bars: Control-bar vs 'Nopal (32%) with PP pulp Jam' bar (15 g); and 100 g Tortillas vs. Tortillas with Nopal (48%).\                                                                ↓ GLU (*p* \< 0.05)\
                                                                                                                                                                                                       Dose: Twice a day, three-weeks. Control trial                                                                                                                                                                            Tortilla and PP pulp jam bars: ↓ GLU (*p* \< 0.05)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PP: Prickly Pear; OGTT: Oral Glucose Tolerance test; CHO: Carbohydrate; PRO: Protein; GLU: Blood Glucose; INS: Serum insulin; Leu: Leucine; AUC: Area Under the Curve; NS: Not Significant; ↓: Decrease; ↑: Increase; Note: 'OpunDia^©^' is a capsule supplement containing 75% Cladode and 25% PP fruit extract (Solvent: Water).
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###### 

Risk of bias summary for included studies in this systematic review.

                                                                 Selection Bias   Performance Bias   Detection Bias   Attrition Bias   Reporting Bias   Other Bias   
  -------------------------------------------------------------- ---------------- ------------------ ---------------- ---------------- ---------------- ------------ ---------
  **Prickly Pear Fruit**                                                                                                                                             
  Khouloud et al. (2016) \[[@B39-medicina-55-00138]\]            High             Unclear            High             Unclear          Low              Low          Unclear
  Wolfram et al. (2002) \[[@B40-medicina-55-00138]\]             High             Unclear            High             Unclear          Low              Low          Unclear
  Pimienta et al. (2008) \[[@B42-medicina-55-00138]\]            High             Unclear            High             Unclear          Low              Low          Unclear
  Wiese et al. (2004) \[[@B41-medicina-55-00138]\]               Low              Low                Low              Unclear          Low              Low          Unclear
  **Cladode/leaf**                                                                                                                                                   
  Frati et al. (1983) \[[@B45-medicina-55-00138]\]               Unclear          Unclear            High             Unclear          Low              Low          Unclear
  Frati et al. (1983) \[[@B46-medicina-55-00138]\]               Unclear          Unclear            High             Unclear          Low              Low          Unclear
  Frati et al. (1987) \[[@B48-medicina-55-00138]\]               Unclear          Unclear            High             Unclear          Low              Low          Unclear
  Frati et al. (1991) \[[@B43-medicina-55-00138]\]               High             Unclear            High             High             Low              Low          Unclear
  Frati et al. (1991) \[[@B44-medicina-55-00138]\]               Unclear          Unclear            High             Unclear          Low              Low          Unclear
  Frati et al. (1988) \[[@B47-medicina-55-00138]\]               High             Unclear            High             High             Low              Low          Unclear
  Frati et al. (1990) \[[@B54-medicina-55-00138]\]               High             Unclear            High             Unclear          Low              Low          Unclear
  Guevare-Cruz et al. (2012) \[[@B49-medicina-55-00138]\]        Low              Low                Low              High             Low              Low          Unclear
  Lopez-Romero et al. (2014) \[[@B50-medicina-55-00138]\]        Unclear          Low                High             Unclear          Low              Low          Unclear
  Castaneda-Andrade et al. (1997) \[[@B53-medicina-55-00138]\]   Unclear          Unclear            Low              Unclear          Low              Low          Unclear
  Linares et al. (2007) \[[@B52-medicina-55-00138]\]             Unclear          Low                Low              Unclear          Low              Low          Unclear
  Bacardi-Gascon et al. (2007) \[[@B55-medicina-55-00138]\]      Low              Unclear            High             Unclear          Low              Low          Unclear
  **Combination of Fruit and Cladode/Leaf**                                                                                                                          
  Deldicque et al. (2013) \[[@B56-medicina-55-00138]\]           Low              Unclear            Low              Unclear          Low              Low          Unclear
  Van Proeyen et al. (2012) \[[@B57-medicina-55-00138]\]         Low              Unclear            Low              Unclear          Low              Low          Unclear
  Godard et al. (2010) \[[@B36-medicina-55-00138]\]              Low              Unclear            Low              Unclear          Low              Low          Unclear
  Guevara-Arauza et al. (2011) \[[@B51-medicina-55-00138]\]      Unclear          Unclear            High             Unclear          Low              Low          Unclear

The forms of bias considered included; selection, performance, detection, attribution, reporting and 'other' biases, which were scored either 'low', 'high' or 'unclear'.
